Use of monoclonal antibodies for the diagnosis and treatment of bladder cancer

Hybridoma

Volumn 18, Issue 3, 1999, Pages 219-224

  Syrigos, Konstantinos N ^a,c   Deonarian, Deno P ^a   Epenetos, Agamemnon A ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Antisona Ltd   (United Kingdom)

^c Department of Medical Oncology ^*  (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY;

BLADDER CANCER; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; DIAGNOSTIC VALUE; DRUG CONJUGATION; HUMAN; IMMUNOSCINTIGRAPHY; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; HYBRIDOMAS; IMMUNOCONJUGATES; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; IMMUNOTOXINS; LIPOSOMES; PRODRUGS; RADIOIMMUNODETECTION; RADIOIMMUNOTHERAPY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; URINE;

EID: 0032800546     PISSN: 0272457X     EISSN: None     Source Type: Journal    
DOI: 10.1089/027245799315862     Document Type: Review

References (52)

1. Kohler G, and Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256: 495-497.
2. Kohler G, and Milstein C: Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. Eur J Immunol 1976;6:511-951.
3. Raghavan D, Shipley WU, Garnick MB, Russell PJ, and Richie JP: Biology and management of bladder cancer. N Engl J Med 1990;322:1129-1138.
4. Heney NM, Nocks BN, Daly JJ, Prout GR Jr, Newall JB, Griffin PP, Pen-one TL, and Szyfelbein WA: Ta and T1 bladder cancer: Location, recurrence and progression. Br J Urol 1982;54:152-157.
5. Kunkler RB, Bishop MC, Green DJ, Pimm MV, Price MR, and Frier M: Targeting of bladder cancer with monoclonal antibody NCRC48: A possible approach for intravesical therapy. Br J Urol 1995;76:81-86.
6. Yu LZ, Gu Fl, and Zhang CL: Radioimmunoimaging diagnosis of human bladder carcinoma. Scand J Urol Nephrol 1994;157:13-17.
7. Narayana AS, Loening SA, Slymen DJ, and Culp DA: Bladder cancer: Factors affecting survival. J Urol 1983;130:56-60.
8. Abel PD, Henderson D, Bennett MK, Hall RR, and Williams G. Differing interpretations by pathologist of the pT category and grade of transitional cell cancer of the bladder. Br J Urol 1988;62:339-342.
9. Ooms EC, Anderson WA, Alons CL, Boon ME, and Veldhuizen RW: Analysis of the performance of pathologists in the grading of bladder tumors. Hum Pathol 1983;14:140-143.
10. Fradet Y, Cordon-Cardo C, Thomson T, Daly ME, Whitmore WF Jr, Lloyd KO, Melamed MR, and Old LJ: Cell surface antigens of human bladder cancer defined by mouse monoclonal antibodies. Proc Natl Acad Sci USA 1984;81:224-228.
11. Syrigos KN, Krausz T, Waxman J, Pandha H, Rowlinson-Busza G, Verne J, Epenetos AA, and Pignatelli M: E-cadherin expression in bladder cancer using formalin-fixed, paraffin-embedded tissues: Correlation with histopathological grade, tumor stage and survival. Int J Cancer 1995;64:367-370.
12. Syrigos KN, Harrington K, Waxman J, Krausz T, and Pignatelli M: Altered gamma-catenin expression correlates with poor survival in patients with bladder cancer. J Urol 1998;160:1889-1893.
13. Casetta G, Piana P, Cavallini A, Vottero M, and Tizzani A: Urinary levels of tumor associated antigens (CA 19-9, TPA and CEA) in patients with neoplastic and non-neoplastic urothelial abnormalities. Br J Urol 1993;72:60-64.
14. Liu BC, Neuwirth H, Zhu LW, Stock LM, Dekernion JB, and Fahey JL: Detection of onco-fetal bladder antigen in urine of patients with transitional cell carcinoma. J Urol 1987;137:1258-1261.
15. Tizzani A, Casetta G, Piana P, and Piantino P: CA-50 as tumor marker in transitional bladder carcinoma. Br J Urol 1989;63:616-618.
16. Zhu SS, Zhang YC, Hu RZ, Ye ZQ, Li CJ, and Lin QA: Clinical studies on bladder tumor-associated antigen in serum of patients with bladder cancer by using monoclonal antibody and sandwich ELISA. J Tongji Med Univ 1990;10:48-51.
17. Huland E, Huland H, and Schneider AW: Quantitative immunocytology in the management of patients with superficial bladder carcinoma. I. A marker to identify patients who do not require prophylaxis. J Urol 1990;144:637-640.
18. Murphy WM: Current status of urinary cytology in the evaluation of bladder neoplasms. Hum Pathol 1990;21:886-896.
19. Lin CW, Young DA, Kirley SD, Khaw AH, and Prout GR Jr: Detection of tumor cells in bladder washings by a monoclonal antibody to human bladder tumor-associated antigen. J Urol 1988; 140:672-677.
20. Sheinfeld J, Reuter VE, Melamed MR, Fair WR, Morse M, Sogani PC, Herr HW, Whitmore WF, and Cordon-Cardo C: Enhanced bladder cancer detection with the Lewis X antigen as a marker of neoplastic transformation. J Urol 1990;143:285-288.
21. Huland E, Huland H, Meier T, Baricordi O, Fradet Y, Grossman HB, Hodges GM, Messing EM, and Schmitz-Draeger BJ: Comparison of 15 monoclonal antibodies against tumor-associated antigens of transitional cell carcinoma of the human bladder. J Urol 1991;146:1631-1636.
22. Masuko T, Sugahara K, Kamiya T, and Hashimoto Y: Increase in murine monoclonal-antibody-defined urinary antigens in patients with bladder cancer and benign urogenital disease. Int J Cancer 1989;44:582-588.
23. Syrigos KN, and Epenetos AA: Radioimmunotherapy of ovarian cancer. Hybridoma 1995;14:121-124.
24. Li L, Zhang Y, Lin Q, Li C, and He M: Clinical application of monoclonal antibody-drug conjugate to immunotargeting chemotherapy of bladder cancer. Chin Med J Engl 1995;108: 764-768.
25. Britton KE, Mather SJ, and Granowska M: Radiolabeled monoclonal antibodies in oncology. III. Radioimmunotherapy. Nucl Med Commun 1991;12:333-347.
26. Thiesen HJ, Juhl H, and Arndt R: Selective killing of human bladder cancer cells by combined treatment with A and B chain ricin antibody conjugates. Cancer Res 1987;47:419-423.
27. Vitetta ES, and Thorpe PE: Immunotoxins containing ricin or its A chain. Semin Cell Biol 1991;2:47-58.
28. Vitetta ES, Thorpe PE, and Uhr JW: Immunotoxins: Magic bullets or misguided missiles? Immunol Today 1993;14:252-259.
29. Timar J, McIntosh DP, Henry R, Cumber AJ, Parnell GD, and Davies AJ: The effect of ricin B chain on the intracellular trafficking of an A chain immunotoxin. Br J Cancer 1991;64:655-662.
30. Wawrzynczak EJ, Cumber AJ, Henry RV, May J, Newell DR, Parnell GD, Worrell NR, and Forrester JA: Pharmacokinetics in the rat of a panel of immunotoxins made with abrin A chain, ricin A chain, gelonin, and momordin. Cancer Res 1990;50:7519-7526.
31. Wawrzynczak EJ, Cumber AJ, Henry RV, and Parnell GD: Comparative biochemical, cytotoxic and pharmacokinetic properties of immunotoxins made with native ricin A chain, ricin A1 chain and recombinant ricin A chain. Int J Cancer 1991;47:130-135.
32. Wawrzynczak EJ, Henry RV, Cumber AJ, Parnell GD, Derbyshire EJ, and Ulbrich N: Biochemical, cytotoxic and pharmacokinetic properties of an immunotoxin composed of a mouse monoclonal antibody Fib75 and the ribosome-inactivating protein alpha-sarcin from Aspergillus giganteus. Eur J Biochem 1991;196:203-209.
33. Sarosdy MF, Hutzler DH, Yee D, and von Hoff DD: In vitro sensitivity testing of human bladder cancers and cell lines to TP-40, a hybrid protein with selective targeting and cytotoxicity. J Urol 1993;150:1950-1955.
34. Siegall CB: Targeted therapy of carcinomas using BR96 sFv-PE40, a single-chain immunotoxin that binds to the Le(y) antigen. Semin Cancer Biol 1995;6:289-295.
35. Theuer CP, FitzGerald DJ, and Pastan I: A recombinant form of Pseudomonas exotoxin A containing transforming growth factor alpha near its carboxyl terminus for the treatment of bladder cancer. J Urol 1993;149:1626-1632.
36. Battelli MG, Polito L, Bolognesi A, Lafleur L, Fradet Y, and Stirpe F: Toxicity of ribosome-inactivating proteins-containing immunotoxins to a human bladder carcinoma cell line. Int J Cancer 1996;65:485-490.
37. Suzuki S, Uno S, Fukuda Y, Aoki Y, Masuko T, and Hashimoto Y: Cytotoxicity of anti-c-erbB-2 immunoliposomes containing doxorubicin on human cancer cells. Br J Cancer 1995;72:663-668.
38. Bassett JB, Anderson RU, and Tacker JR: Use of temperature-sensitive liposomes in the selective delivery of methotrexate and cisplatinum analogues to murine bladder tumor. J Urol 1986;135: 612-615.
39. Bassett JB, Tacker JR, Anderson RU, and Bostwick D: Treatment of experimental bladder cancer with hyperthermia and phase transition liposomes containing methotrexate. J Urol 1988;139: 634-636.
40. Frangos DN, Killion JJ, Fan D, Fishbeck R, von Eschenbach AC, and Fidler IJ: The development of liposomes containing interferon alpha for the intravesical therapy of human superficial bladder cancer. J Urol 1990;143:1252-1256.
41. Killion JJ, Fan D, Bucana CD, Frangos DN, Price JE, and Fidler IJ: Augmentation of antiproliferative activity of interferon alfa against human bladder tumor cell lines by encapsulation of interferon alfa within liposomes. J Natl Cancer Inst 1989;81:1387-1392.
42. Killion JJ, Fishbeck R, Bar-Eli M, and Chernajovsky Y: Delivery of interferon to intracellular pathways by encapsulation of interferon into multilamellar liposomes is independent of the status of interferon receptors. Cytokine 1994;6:443-449.
43. Philpott GW, Bower RJ, and Parker CW: Selective iodination and cytotoxicity of tumor cells with an antibody-enzyme conjugate. Surgery 1973;74:51-58.
44. Philpott GW, Shearer WT, Bower RJ, and Parker CW: Selective cytotoxicity of hapten-substituted cells with an antibody-enzyme conjugate. J Immunol 1973;111:921-929.
45. Bagshawe KD: Antibody directed enzymes revive anti-cancer prodrugs concept. Br J Cancer 1987;56:531-532.
46. Bagshawe KD, Springer CJ, Searle F, Antoniw P, Sharma SK, Melton RG, and Sherwood RF: A cytotoxic agent can be generated selectively at cancer sites. Br J Cancer 1988;58:700-703.
47. Senter PD, Saulnier MG, Schreiber GJ, Hirschberg DL, Brown JP, Hellstrom I, and Hellstrom KE: Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc Natl Acad Sci USA 1988;85:4842-4846.
48. Senter PD, Schreiber GJ, Hirschberg DL, Ashe SA, Hellstrom KE, and Hellstrom I: Enhancement of the in vitro and in vivo antitumor activities of phoshorylated mitomycin C and etoposide derivatives by monoclonal antibody-alkaline phosphatase conjugates. Cancer Res 1989;49:5789-5792.
49. Syrigos KN, Rowlinson-Busza G, and Epenetos AA: In vitro cytotoxicity following specific activation of amygdalin by β glucosidase conjugated to a bladder cancer-associated monoclonal antibody. Int J Cancer 1998;78:712-719.
50. Syrigos KN, Pignatelli M, Gravas S, Harrington K, Leventis A, Kehayas P, and Epenetos AA: MUC1 mucin expression in bladder cancer: Correlation with histopathological data. Br J Urol 1997;80:71.
51. Syrigos KN, Khawaja M, Krausz T, Williams G, and Epenetos AA: Intravesical administration of radiolabeled tumor associated monoclonal antibody in bladder cancer. Acta Oncol 1999;38:379-382.
52. Syrigos KN, Harrington KJ, and Pignatelli M: Role of adhesion molecules in bladder cancer: An important part of the jigsaw. Urology 1999;53:428-434.